Diagnostic Value of microRNA-375 as Future Biomarker for Prostate Cancer Detection: A Meta-Analysis

Nițușcă, Diana; Marcu, Anca; Șeclăman, Edward; Bardan, Răzvan; Sîrbu, Ioan Ovidiu; Bălăcescu, Ovidiu; Bucur, Adina; Ursoniu, Sorin; Marian, Cătălin

doi:10.3390/medicina58040529

Cited by 5 publications

(7 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is believed that miRNAs can play an important role in the diagnosis of many tumors [ 15 ]. It has been found that miRNAs are closely related to the occurrence and progression of prostate cancer, and it is believed that miRNAs are important in both the early diagnosis and malignant progression of prostate cancer [ 16 ]. Therefore, in this study, we screened miRNAs with differential expression in prostate cancer by miR microarray, and verify the potential of the miRNAs in prostate cancer diagnosis and explore the role of the validated miRNAs in the malignant progression of prostate cancer to open a new path for miRNA-based treatment of prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

Preliminary study on miRNA in prostate cancer

Abudoubari,

Bu,

Mei

et al. 2023

World J Surg Onc

View full text Add to dashboard Cite

Objective To screen for miRNAs differentially expressed in prostate cancer and prostate hyperplasia tissues and to validate their association with prostate cancer. Methods Patients diagnosed by pathology in the Department of Urology of the First Affiliated Hospital of Xinjiang Medical University from October 2021 to June 2022 were selected, and their general clinical information, blood samples, and prostate tissue samples were collected. miRNA microarray technology was performed to obtain differentially expressed miRNAs in prostate cancer and hyperplasia tissues, and miRNAs to be studied were screened by microarray results and review of relevant literature. The detection of miRNA expression in the patients’ blood and prostate tissue samples was measured. The miRNA-222-mimics were transfected into PC3 cells, and cell biology experiments such as CCK8, scratch, Transwell, and flow cytometry were performed to detect the effects of overexpressed miRNA-222 on the growth and proliferation, invasive ability, apoptotic ability, and metastatic ability of prostate cancer cells. Results The results of the miRNA microarray showed that there were many differentially expressed miRNAs in prostate cancer and hyperplasia tissues, and four miRNAs, miRNA-144, miRNA-222, miRNA-1248, and miRNA-3651 were finally selected as the subjects by reviewing relevant literature. The results showed that the expression of miRNA-222 in prostate cancer tissues was lower than that in prostate hyperplasia tissues (P < 0.05). The expression of miRNA-222, miRNA-1248, and miRNA-3651 in blood samples of prostate cancer patients was lower than that in prostate hyperplasia patients (P < 0.05). The analysis results indicated that the f/t ratio and the relative expression of miRNA-222 and miRNA-1248 were independent influences of prostate cancer (P < 0.05), in which overexpression of miRNA-222 decreased the proliferative, invasive, and metastatic abilities of PC3 cells and enhanced the level of apoptosis of cancer cells. Conclusions Although there was no significant change in the overall incidence of prostate cancer in this study, significant changes occurred in the incidence of prostate cancer with different characteristics. In addition, the nomogram prediction model of prostate cancer-specific survival rate constructed based on four factors has a high reference value, which helps physicians to correctly assess the patient-specific survival rate and provides a reference basis for patient diagnosis and prognosis evaluation.

show abstract

Section: Discussionmentioning

confidence: 99%

Preliminary study on miRNA in prostate cancer

Abudoubari,

Bu,

Mei

et al. 2023

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…Among these 12 miRNAs, miR‐141 and miR‐375 were confirmed to be upregulated in metastatic PCa 70 . Additionally, recent meta‐analyses showed that miR‐141 and miR‐375 have high diagnostic values for PCa 71,72 …”

Section: The Clinical Significance Of Extracellular Mirnas In Liquid ...mentioning

confidence: 96%

“…70 Additionally, recent meta-analyses showed that miR-141 and miR-375 have high diagnostic values for PCa. 71,72 Common limitations of circulating miRNA studies are that they have relatively small sample sizes and focus on evaluation of specific miRNAs. Thus, we investigated the utility of comprehensive analysis of serum miRNAs using the largest sample sets.…”

Section: Diagnostic Extracellular Mirnasmentioning

confidence: 99%

miRNAs in prostate cancer: Intercellular and extracellular communications

Urabe

Yamamoto²,

Kimura

2022

Int J of Urology

View full text Add to dashboard Cite

Prostate cancer is the most prevalent male cancer in Western Europe and North America. Although new drugs were recently approved, clinical challenges such as accurately predicting and screening drug‐resistant prostate cancer remain. microRNAs are short noncoding RNA molecules that participate in gene regulation at the post‐transcriptional level by targeting messenger RNAs. There is accumulating evidence that intracellular microRNAs play important roles as promoters or inhibitors of prostate cancer progression. Additionally, recent studies showed that microRNAs are encapsulated in extracellular vesicles and shuttled into the extracellular space. Transfer of extracellular microRNAs contributes to intercellular communication between prostate cancer cells and components of the tumor microenvironment, which can promote prostate cancer progression. Furthermore, due to their encapsulation in extracellular vesicles, extracellular microRNAs can be stably present in body fluids which contain high levels of RNase. Thus, circulating microRNAs have great potential as noninvasive diagnostic and prognostic biomarkers for prostate cancer. Here, we summarize the roles of intracellular and extracellular microRNAs in prostate cancer progression and discuss the potential of microRNA‐based therapeutics as a novel treatment strategy for prostate cancer.

show abstract

“…In western countries, prostate malignant tumor is considered as the common cancer, especially in elderly men [ 1 ]. It was reported that the occurrence rate of prostate malignant tumor raised every year, which severely affected the physical and psychological status of these patients [ 2 , 3 ]. Many studies reported that patients with prostatic cancer in the early phase who underwent timely treatment could gain a more than 5-year survival rate, while those in the end stage showed an obviously less than 5-year survival rate [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

“…e inclusion criteria were as follows: (1) those who were diagnosed as suspicious prostate cancer with over 30 years of age and elevated levels of prostate-specific antigen (PSA) (≥4.0 ng/mL). (2) ose who had no history of radiotherapy, chemotherapy, and endocrine treatment. (3) e examinations of contrast-enhanced ultrasonography, MRI, and prostate biopsy were performed.…”

Section: Introductionmentioning

confidence: 99%

Study on the Diagnostic Value of Contrast-Enhanced Ultrasound and Magnetic Resonance Imaging in Prostate Cancer

Pang¹,

Zhang²,

Chen³

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. The aim is to study the different roles of single and joint application of magnetic resonance imaging (MRI) and contrast-enhanced ultrasound (CEUS) in prostate malignant tumors. Methods. 72 patients with prostate masses who underwent CEUS and MRI examination in our hospital from October 2021 and March 2022 were enrolled in this research. The differentially diagnostic roles of CEUS, MRI, and CEUS combined MRI for prostate cancer was assessed on basis of pathological findings as the reference standard. The specificity and sensitivity of the joint application for prostate malignant tumors with various prostate-specific antigen (PSA) levels were also evaluated. Results. The sensitivity of CEUS, MRI, and the joint application for prostate cancer were 72.1%, 74.4%, and 90.7%, respectively. Compared with single application, the sensitivity of CEUS combined with MRI was significantly higher. The specificity of MRI, CEUS, and the combination of the two for prostate cancer were 82.8%, 79.3%, and 89.7%, respectively, and the statistical differences for specificity were not found. The area under ROC curve (AUC) of CEUS combined with MRI in prostate malignant tumor diagnosis was obviously more than that of CEUS and MRI ( P < 0.05 ). CEUS combined with MRI has relative high sensitivity in these patients with different levels of PSA. Conclusions. Contrast-enhanced ultrasound combined with MRI can significantly improve the sensitivity and specificity of prostate cancer diagnosis so that patients can be better diagnosed in advance.

show abstract

Diagnostic Value of microRNA-375 as Future Biomarker for Prostate Cancer Detection: A Meta-Analysis

Cited by 5 publications

References 45 publications

Preliminary study on miRNA in prostate cancer

Preliminary study on miRNA in prostate cancer

miRNAs in prostate cancer: Intercellular and extracellular communications

Study on the Diagnostic Value of Contrast-Enhanced Ultrasound and Magnetic Resonance Imaging in Prostate Cancer

Contact Info

Product

Resources

About